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Abstract
Objective: our objective was to evaluate the impact of
routine use of double-J stents on the incidence of uri-
nary tract infection after renal transplantation.
Methods: We  conducted  a  retrospective-comparative
single-centre study in 310 consecutive adult deceased
donor  kidney  recipients  transplanted  from  2002  to
2006.  Patients  were  divided  in  two  groups,  with  or
without  urinary  stent  implantation.  to  evaluate  the
predictive factors for UtI, donor and recipients pre-
and  post-transplantation  data  were  analysed.  Early
urological complications and renal function within 12
months of transplantation were included as well.
Results: a  total  of  157  patients  were  enrolled  to  a
stent (St) and 153 patients to a no-stent (nSt) group.
the rate of urinary tract infection at three months was
similar between the two groups (43.3% St vs. 40.1%
nSt, p = 0.65). of the identified pathogens Entero-
coccus and Escherichia coli were the most common
species.  In  multivariate  analysis  neither  age  nor  im-
munosuppressive agents, BMI or diabetes seemed to
have influence on the rate of UtI. When compared to
males, females had a significantly higher risk for UtI
(54.0% vs. 33.5%).
Conclusion: Prophylactic stenting of the ureterovesical
anastomosis does not increase the risk of urinary tract
infection in the early postoperative period.
Key words: kidney transplantation, anastomosis, urete  -
ro  vesical stent, urinary tract infection, sepsis
IntRodUctIon
Urinary tract infections (UtI) are the most common
infectious  complications  in  patients  receiving  renal
transplantation for end stage kidney disease [1, 2]. UtI
could be associated with an increased morbidity and
mortality risk, can worsen the graft and patient survival
in renal transplant recipient [3, 4]. a significant pro-
portion of kidney transplant recipients with UtIs may
develop acute pyelonephritis, which is an independent
risk factor for deterioration of graft function [5].
Some  recent  studies  suggest  routine  prophylactic
stenting of ureterovesical anastomosis at the time of
graft  implantation  to  reduce  the  incidence  of  early
postoperative major urologic complications, as urinary
leaks and stenosis [6-8]. others advocate the use of
stent  only  in  selective,  difficult  cases  while  routine
stenting  could  be  associated  with  specific  complica-
tions as haematuria, migration, malposition or compli-
cations of removal [9, 10].
It has been shown, that urinary stenting could lead
to a significant increase of infections of lower and up-
per  urinary  tract  in  immunocompromised  patients
[11]. although, whether universal routine stenting of
the ureteroneocystostomy is a real risk factor for the
development of severe urinary tract infection (UtI)
after renal transplantation is still controversial. there-
fore, to help further clarify this issue, we compared the
frequency of UtI in our cohort of deceased donor
kidney transplant recipient transplanted with or with-
out ureteric stent implantation.
PatIEntS and MEtHodS
StUdy PoPUlatIon
this  is  a  retrospective,  observational  study  of  de-
ceased donor renal allograft recipients who were con-
secutively  transplanted  at  University  Hospital  Essen,
Germany between January 2002 and december 2006
(n = 310). data for this study were obtained from our
transplant database and review of electronic and pa-
per-based medical records. all adult (>18 years) de-
ceased  donor  kidney  transplantations,  except  com-
bined multiorgan transplants were considered. living
donor transplantations were not included in the study.
transplant procedures were performed in accordance
with standard techniques. double-J ureteral catheters
were placed intraoperatively per the surgeonﾴs discre-
tion based on ureter, bladder and anastomotic charac-
teristics until June 2004 and on routine basis there-
after. 157 patients were enrolled to a stent- (St) and
153 patients to a no-stent (nSt) group. Recipient and
donor demographic and laboratory data, at the time of
transplantation and afterwards were reviewed.
Urinary  tract  infection  was  defined  as  the  patient
having one of the following symptoms dysuria, fever,
urgency, frequency, suprapubic tenderness, and positive
urine culture with ≥105 microorganism/cm3 or two of
the above signs and pyuria (>WBc/mm3) or <105 mi  -
cro  organism/cm3 if patient was on antibiotics.
Intravenous cefazoline (2g) was given once periop-
eratively within 30 minutes prior to skin incision and
repeated  once  when  operation  exceeded  3  hours.  a
dose of single strength trimetoprim/sulfametoxazole
(tMP/SMX) was started on day 2 or 3 and continued
every second day for four to six months. the foley
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4. Heuer_Umbruchvorlage  12.07.10  14:30  Seite 297catheter was removed on postoperative days 4-7. Urine
samples were collected by aseptic technique. all stents
were removed by cystoscopy under aseptic conditions
4-6 weeks after transplantation. antibiotic prophylaxis
was not given before removing the stents. the dou-
ble-J catheter tips were cultured for bacteria and fungi.
Immunosuppression  consisted  of  methylpred-
nisolone  (500  mg  given  intraoperatively,  followed  by
sequential tapering to daily oral prednisone 30 mg by
one  week,    10  mg  at  one  month  and  5  mg  at  6-12
months),  mycophenolate-mofetil (2g/d postoperative-
ly with dose adjustment for side effects), calcineurin-
inhibitors (tacrolimus or cyclosporin-a started within
24 hours after surgery) and/or Il-2 receptor blockers
(basiliximab, daclizumab). Estimated glomerular filtra-
tion rate (eGfR) was calculated using the MdRd for-
mula:eGfR  (ml/min/1.73m2)  =  186  x  crS-1.154  x
age-0.203 x 0.742 (if female). „Extra risk“ recipients
were defined as recipients older than 60 years or older
than 50 years with at least one of the following risk
factors: coronary heart disease,peripheral arterial dis-
ease (Pad, grade IIa or higher), diabetes mellitus [12].
Patients with findings suggestive of UtI were hospital-
ized for further work-up and treatment, if necessary.  
UREtERovESIcal IMPlantatIon
the technique of the ureteroneocystostomy consisted
of  an  end-to-side  extravesical  implantation  of  the
ureter onto the anterior bladder wall, modified from
the lich-Gregoire procedure. In summary, a cc. 1.5 cm
incision of detrusor  was made on the posterolateral
aspect of bladder, followed by sharp dissection of mu-
cosa. the anastomosis was constructed between the
spatulated distal donor ureter and a small bladder mu-
cosal nick made after myotomy incision. a watertight
mucosa-to-mucosa anastomosis, using 5/0 or 6/0 ab-
sorbable running sutures was performed of the spatu-
lated ureter to a distal mucosal opening, followed by
the creation of submucosal tunnel by approximation
of seromuscular layers using absorbable sutures.
StatIStIcal analySIS
data are given as counts (with percentages) or mean
values (with Sds). Medians (with interquartile ranges
[IQR]) are reported for non-normally distributed data.
for  univariate  comparisons  between  the  groups,  we
used  chi-square  or  fisher’s  exact  test  for  categorical
variables,  and  by  Student’s  t  or  Mann  Whitney  rank
sum test for continuous variables. Box plots follow the
standard format as used by SPSS (version 15). P-values
less than 0.05 were accepted as statistically significant.
We used multivariable analysis in order to adjust for
baseline imbalances between the groups. a logistic re-
gression model was developed to predict urinary tract
infection, using various demographic and medical vari-
ables  as  covariates.  By  stepwise  backward  selection,
non-predictive variables were eliminated using a thres  -
hold of p< 0.1. the explanatory power of the final
model  was  examined  by  calculating  nagelkerke's  R2
coefficient,  which  ranges  between  0  (no  predictive
power at all) and 1 (UtI incidence predictable with
100% certainty).
RESUltS
during the study period 310 patients were eligible for
analysis. Patient characteristics and transplantation re-
lated data are summarized in table 1. all patients were
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Table 1. Baseline characteristics of the two group of recipients.
ST group NST group P value
No. of pts. 157 (50.6%) 153 (49.4%) -
Mean age (years) 53.0 (12.1) 48.5 (13.7) 0.003
No. of males 94 (59.9%) 92 (60.1%) 1.0
Body mass index (kg/m2) 25.3 (4.3) 24.4 (4.0) 0.07
Primary transplant 123 (78.3%) 114 (74.5%) 0.91
Duration of pretransplant dialysis (months) 79.3 (49.5) 66.2 (34.8) 0.008
Mean cold ischemia time (hrs) 15.6 (6.0) 17.7 (8.3) 0.01
Number of HLA mismatches 0.81
0 21 (13%) 23 (15%)
1 14 (9%) 16 (11%)
2 29 (19%) 32 (21%)
3 35 (22%) 27 (18%)
4 34 (22%) 33 (22%)
5 12 (8%) 15 (10%)
6 12 (8%) 7 (5%)
Gender mismatch 73 (46.5%) 81 (52.9%) 0.55
“Extra risk” recipients 69 (43.9%) 49 (32.0%) 0.035
4. Heuer_Umbruchvorlage  12.07.10  14:30  Seite 298followed for at least one year. there was no significant
difference between the stented (St) and non-stented
(nSt) groups with respect to underlying kidney dis-
ease,  body  mass  index  (BMI),  gender  or  Hla  mis-
matches. the patients from the St group were older,
the cold ischemia time was longer and these patients
were  dialysed  longer  before  transplantation.    donor
characteristics were summarized in table 2. there was
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Table 2. donor demographics.
ST group NST group P value
Mean age (years) 52.3 (16.3) 46.8 (15.9) 0.003
No. of males 81 (52.3%) 78 (51.3%) 0.91
Body mass index (kg/m2) 26.2 (4.8) 25.0 (4.9) 0.033
Any relevant comorbidity 79 (51.0%) 82 (53.9%) 0.65
Cause of death 0.28
Intracerebral bleeding 93 (59%) 74 (48%)
Hypoxia 27 (17%) 30 (20%)
Cardiovascular 17 (11%) 21 (14%)
Trauma 13 (8%) 24 (16%)
Other 7 (4%) 4 (3%)
Median length of ICU stay before  4 (IQR 2 to 8) 3 (IQR 2 to 8) 0.99
explantation (days)
Median donor serum  0.90 0.90 0.96
creatinin (umol/l) at explantation (IQR 0.63 to 1.30) (IQR 0.70 to 1.25)
Table 3. clinical results in the two groups.
ST group NST group P value
(n = 157) (n= 153)
Urinary tract infection 68 (43.3%) 61 (40.1%) 0.65
Ureteric leakage 13 (8.3%) 9 (5.9%) 0.51
Ureteric stenosis 2 (1.3%) 2 (1.3%) 1.0
Hematoma 9 (5.7%) 11 (7.2%) 0.65
Wound infection 11 (7.0%) 17 (11.2%) 0.24
Acute Rejection 36 (22.9%) 53 (34.6%) 0.024
Fig. 1. Microbial species cultures from
129  recipients  having  clinical  symp-
toms of UtI.
4. Heuer_Umbruchvorlage  12.07.10  14:30  Seite 299also no significant difference with regard to gender,
relevant co-morbidities, cause of death, median length
of IcU stay or kidney function. However, donors for
stented group were older and their BMI was higher.
the mean incidence of diabetes was 12.9%.
one hundred twenty-nine infection episodes of uri-
nary tract infections were diagnosed in 310 (41.6%) re-
cipients. the rate of UtI at three months was similar
in the St group compared to nSt group (43.3% vs.
40.1%), but without reaching significance (p = 0.65).
there was no graft loss as a result of stent-related in-
fectious complications. figure 1 depicts the causative
pathogens of UtI.
the overall rate of urinary tract complications in
the  two  groups  were  also  summarized  in  table  3.
anastomotic stenosis rate (1.3 %) was similar in the
nSt versus the St group, urinary leakage occurred in
6.8% of all recipients, 8.3% in St- vs. 5.9% in nSt
group,  respectively.  We  observed  fewer  episodes  of
acute  rejection  in  St  group  (22.9%  vs.  34.6%,  p  =
0.024). Wound infection occurred in 7% vs. 11.2% of
patients (ns).  In multivariate analysis (table 4) the fol-
lowing categorical variables had no impact on the rate
of UtI: age at transplantation, diabetes mellitus, BMI,
duration of pretransplant dialysis, duration of surgery
and cold ischemia time. However, female gender sig-
nificantly (p<0.001) affected the incidence of urinary
tract infection (54.0% vs. 33.5%, relative risk 1.4, 95%-
cI 1.2 to 1.8). Graft function did not differ significant-
ly between the two groups of recipients (fig. 2).
dIScUSSIon
Renal  transplantation  is  a  widely  accepted  treatment
for patients with end-stage kidney disease. despite of
well established surgical technique and a continuous
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Table 4. Results of multivariate regression analyses of predictors for UtI.
Variable Coefficient in Initial  P value Coefficient in final  P value
regression model regression model
(with 95%-CI)
Age (per year increase) 0.998 0.93 -
Gender (male vs. female) 0.395 0.002 0.40 (0.23 to 0.70) 0.001
BMI (per kg/m2) 1.005 0.88 -
Diabetes 1.0 1.0 -
“Extra risk” recipients 1.625 0.33 1.68 (0.95 to 2.97) 0.077
Duration of pretrans-plant dialysis  0.998 0.59 -
(per month increase)
Duration of surgery (per minute increase) 1.001 0.75 -
Urinary stenting 1.169 0.62 -
Tacrolimus 0.986 0.964 -
Cold ischemia time (per minute increase) 0.980 0.307 -
Explanatory power of the final model was limited, as nagelkerke’s R2 was 0.08.
Fig.  2.  Recipient  eGfR  (in  ml/1.73
m2)  at  transplantation  and  after  1,  4
and 52 weeks in the two groups.
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past two decades, the rate of urinary tract complica-
tions remains still considerable common and may vary
between 2-15 % [12, 13]. these include urinary leak,
obstruction,  stenosis,  necrosis  and  vesicoureteral  re-
flux.  these  complications  increase  morbidity,  delay
graft  function,  and  occasionally  may  lead  to  graft
and/or patient loss [14].
Recently, many studies, including a prospective ran-
domized trial, advocate stenting of the ureterovesical
anastomosis to reduce the rate of these complication
[15-18]. opponents counter that the stent can migrate,
could have bad permeability, could contribute to post-
operative pain and stone formation [19, 20]. others
advocate that  stent can increase postoperative infec-
tion risk, can erode the lumen, can exacerbate long-
term  stricturing  of  the  anastomosis  and  the  use  of
stenting should be restricted to difficult ureterovesical
anastomosis [21].
currently, no controlled randomized study evaluat-
ed the rate of urinary tract infections with and without
ureteral stent implantation, and there is no clearly de-
fined consensus among transplant surgeons with re-
gard to routine stenting of the vesicoureteral anasto-
mosis during renal transplantation. therefore, to fur-
ther evaluate this issue we conducted a comparative-
retrospective study to analyse the frequency of UtI in
a cohort of deceased donor kidney transplant recipi-
ents who were operated either with or without dou-
ble-J placement in our center. We also investigated the
influence  of  stenting  on  renal  function  and  major
ureteric complications (leakage, obstruction).
Urinary tract infection (UtI) occurred in 41.6% of
our patients. the reported frequency of UtI may vary
from 18% to 79% [1, 22]. differences in the defini-
tion,  follow-up  period,  immunosuppression  and  the
use  of  antimicrobial  prophylaxis  could  explain  this
wide range. a recent report showed that stenting of
the vesicoureteral anastomosis is a predictor factor for
UtI after kidney transplantation [6]. others could not
identify such an association [7-9]. our study has also
failed  to  demonstrate    an  increased  risk  of  UtI  in
stented recipients.
other factors that have been also associated with a
higher risk of UtI in renal transplant recipients in-
clude female gender, age, diabetes mellitus the func-
tion of the transplanted kidney and prolonged dialysis
pre-transplantation [10]. However, except female gen-
der, none of them was independently associated with a
higher risk of UtI in our study. We did also not find
that advanced age would increase the risk of UtI in
our  renal  transplant  recipients.  although  earlier  re-
ports  have  noted  a  higher  incidence  of  UtI-related
complications such as pyelonephritis and urosepsis [5],
we did also not observe such an increase. We observed
a  significant  decrease  in  acute  rejection  rate  in  the
stented patient group (22.9% vs 34.6%). one specula-
tive explanation could be that stenting allows early de-
compression  of  the  anastomosis  to  ensure  free
drainage despite mucosal oedema, although auxiliary
studies could further evaluate this issue.
Previous published studies report conflicting results
whether a history of diabetes increases or does not in-
fluence the renal transplant patient's risk of develop-
ing a UtI [11, 12]. diabetic patients have been shown
to  have  a  higher  incidence  of  significant  bacteriuria
therefore we expected this trend to continue after re-
nal  transplantation.  However,  we  did  not  find  pre-
transplant diabetes to be associated with an increased
incidence of UtI in our renal transplant population.
the lack of impact may be due to the overall low inci-
dence of diabetic recipients (12.9%) in our study pop-
ulation.
the pathogens isolated from renal transplant recipi-
ents  with  UtI  have  been  previously  reported  to  be
similar to those causing UtI in the general population
[23]. a renal transplant series reported recently, that
Escherichia  coli  would  be  the  most  common
uropathogen (32%) and Enterococcus isolated in 18%
[24,  25].  our  study  identified  Enterococcus  spp.  as
leading  uropathogen  causing  UtI  after  renal  trans-
plantation. these observations are in correlation with
the data of alangaden et al. identifying first that Ente-
rococcus spp. could be the predominant pathogens in
UtIs in kidney allograft recipients [1].
there are some limitations of our study. first, due
to  retrospective  comparative  data  analyses  and  rela-
tively small number of patients we hesitate to draw
firm conclusion from the observed associations. Sec-
ondary,  in  the  first  study  period  ureterovesical  stent
were rather implanted on a subjective basis when the
transplant  surgeon  experienced  an  unfavourable
anatomy and expected complications.
despite these biases, we would conclude that rou-
tine use of double-J stents for prophylactic stenting of
the ureteroneocystostomy does not affect significantly
the rate of urinary tract infection in deceased donor re-
nal transplant recipient population. Whether longer du-
ration of stenting, immunosuppression with induction
therapy by multiple transplants or living donor trans-
plantation has a further influence on incidence of UtI
is still unclear. It is therefore prudent to continue mon-
itoring possible relationship between double-J implan-
tation and UtI in renal transplant recipients.
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